301 filings
Page 3 of 16
8-K
4aninng6
22 Dec 22
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
9:00am
8-K
7nvbn2g
20 Dec 22
Oragenics, Inc. Receives NYSE American Notice
4:55pm
8-K
x5tija
19 Dec 22
Oragenics, Inc. Announces New Chair
4:51pm
8-K
lqd3mh ewsla8
16 Dec 22
Departure of Directors or Certain Officers
4:05pm
8-K
63guya5shxhsccfk
16 Nov 22
Departure of Directors or Certain Officers
4:15pm
8-K
20l 0zdzse2y27
3 Oct 22
Regulation FD Disclosure
9:15am
8-K
o6et s7tortreq8r
30 Sep 22
Oragenics Issues Letter to Shareholders
9:00am
8-K
x1ryirbb66bp636c0x
24 Aug 22
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
8:02am
8-K
g54po 7hfu
3 Aug 22
Departure of Directors or Certain Officers
4:05pm
8-K
1j7j shjy
8 Jul 22
Departure of Directors or Certain Officers
4:04pm
8-K
xgu6uawhtnq0dfi
23 Jun 22
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
5:22pm
8-K
vwexr18 4funocue
17 May 22
Oragenics Issues Letter to Shareholders
9:30am
8-K
5vutc0lipnqi20n
19 Apr 22
Regulation FD Disclosure
5:14pm
8-K
88eqg7m4 c7l392
6 Apr 22
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
7:45am
8-K
fnc3aqg1 fdkqpnxthir
10 Mar 22
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
7:47am
8-K
p3qo4u 4oewkk
28 Feb 22
Material Modifications to Rights of Security Holders
12:00am
8-K
e7owvb vb59
26 Jan 22
Oragenics Announces Adjournment of Annual Meeting of Shareholders
9:04am
8-K
yyb4wajgab79jdy
20 Dec 21
Oragenics Extends Collaboration with the National Research Council of Canada to Develop
8:19am
8-K
tcrttc0o
20 Dec 21
Departure of Directors or Certain Officers
12:00am
8-K
axo 6vlzzjeo
14 Dec 21
Regulation FD Disclosure
4:05pm